Author
Li Zhou
0 works0 citations
Recent research
- Health & MedicineOpen access
Neoadjuvant Anbenitamab and HB1801 in ERBB2 -Positive Breast Cancer
IMPORTANCE The combination of neoadjuvant taxanes with trastuzumab and pertuzumab remains the cornerstone treatment strategy in ERBB2 -positive breast cancer. Anbenitamab (a ERBB2 -biparatopic antibody that induces profound receptor clustering) and HB1801 (a solvent-free albumin-...